Stratus Versus Cirrus OCT in AMD

This study is currently recruiting participants.

Verified by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery, December 2007

Sponsored by:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Information provided by:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier:	NCT00568191

Purpose

The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected

Condition
Age-Related Macular Degeneration Choroidal Neovascularization

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT

Further study details as provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

Primary Outcome Measures:

Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line [ Time Frame: only 1 examination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan [ Time Frame: 1 examination ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	100
Study Start Date:	October 2007
Estimated Study Completion Date:	December 2007

Groups/Cohorts
1 retinal thickness program Stratus OCT software 4.0
2 retinal cube 200x200 program of Cirrus OCT

Eligibility

Ages Eligible for Study:	55 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients aged > 55 years of either sex presenting with age-related macular degeneration

Criteria

Inclusion Criteria:

Age>55 years
Age-related macular degeneration

Exclusion Criteria:

Not consented patients

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568191

Contacts

Contact: Ilse Krebs, MD

+43171165 ext 94607

Ilse.Krebs@wienkav.at

Locations

Austria
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery	Recruiting
Vienna, Austria, A1030
Contact: Ilse Krebs, MD +43171165 ext 4607 Ilse.Krebs@wienkav.at
Principal Investigator: Ilse Krebs, MD

Sponsors and Collaborators

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Investigators

Principal Investigator:

Ilse Krebs

Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery

More Information

Responsible Party:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery ( Prof Susanne Binder )
Study ID Numbers:	EK 06-007-VK1
Study First Received:	December 4, 2007
Last Updated:	December 4, 2007
ClinicalTrials.gov Identifier:	NCT00568191
Health Authority:	Austria: Ethikkommission

Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

Age-related macular degeneration
choroidal neovascularization
Stratus OCT
Cirrus OCT

Study placed in the following topic categories:

Metaplasia
Eye Diseases
Choroid Diseases
Retinal Degeneration
Macular Degeneration

Neovascularization, Pathologic
Retinal Diseases
Retinal degeneration
Choroidal Neovascularization

Additional relevant MeSH terms:

Uveal Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on January 15, 2009